Rare Disease Phase 3 Deal Benchmarks — Ex-US (2026)
Median upfront of $575M with total deal values reaching $2.6B in Ex-US territory.
Median Upfront
$575M
Total Deal Value
$2.0B
Royalty Range
8.4%–15.2%
Territory Multiplier
0.45x
Understanding Rare Disease Deal Benchmarks at Phase 3
Phase 3 Rare Disease licensing deals in Ex-US territory command a median upfront payment of $575M, with values ranging from $346M at the low end to $781M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the rare disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Full Benchmark Data
Full Benchmark Table
Low, median, and high ranges for upfront payments, total deal values, and royalty rates.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Comparable Deals
See All Comparable Deals
View 2 comparable Rare Disease transactions with upfront payments, total values, and deal structures.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 3 Rare Disease deals in Ex-US territory?
More Expert Insights
Territory impact analysis, royalty negotiation strategies, and deal structure guidance.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Related Benchmarks
$22M upfront
Rare Disease · Preclinical · Ex-US
$54M upfront
Rare Disease · Phase 1 · Ex-US
$169M upfront
Rare Disease · Phase 2 · Ex-US
$1.5B upfront
Rare Disease · Approved · Ex-US
$324M upfront
Oncology · Phase 3 · Ex-US
$232M upfront
Neurology/CNS · Phase 3 · Ex-US
$406M upfront
Immunology · Phase 3 · Ex-US
$554M upfront
Metabolic/Obesity · Phase 3 · Ex-US
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open Deal CalculatorCite This Data
Ambrosia Ventures. (2026). Rare Disease Phase 3 Deal Benchmarks — Ex-US (2026). Retrieved from https://calculator.ambrosiaventures.co/data/rare-disease-phase-3-deals-ex-us
<a href="https://calculator.ambrosiaventures.co/data/rare-disease-phase-3-deals-ex-us">Rare Disease Phase 3 Deal Benchmarks — Ex-US (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://calculator.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=rareDisease&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,900+ verified biopharma transactions. Updated monthly.